CoChat

Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study

Open access
Cameli, Paolo, Refini, Rosa Metella, Bergantini, Laura, d’Alessandro, Miriana, Alonzi, Valerio, Magnoni, Carlo, Rottoli, Paola, Sestini, Piersante, Bargagli, Elena · 2020 · Frontiers in Molecular Biosciences
Cited by 89

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background. Pirfenidone and nintedanib are the sole pharmacological therapies currently approved for idiopathic pulmonary fibrosis (IPF). Limited comparison data is available in literature, despite they are both prescribed for mild-to-moderate disease. Here, we describe our almost ten-years real-life experience with antifibrotic treatment to investigate potential differences in terms of efficacy. Population and methods. We retrospectively recruited patients diagnosed with IPF and treated with pirfenidone or nintedanib at Siena Referral Centre. Clinical, functional, safety and radiological data was collected at baseline and during the follow-up, according to our Centre protocol. Results. We retrospectively recruited 263 IPF patients (139 treated with pirfenidone and 124 with nintedanib) in the study. After 885.3 ± 559.5 days of observation, the median survival was 1224 days. No significant differences were found between pirfenidone and nintedanib in terms of survival and time to decline of forced vital capacity > 10% (p=0.8786 and p=0.1677, respectively). A smaller lung diffusion for carbon monoxide (DLCO) decrease was found after one year of therapy with nintedanib in respect to pirfenidone (p=0,0167). Overall, 21 patients permanently discontinued antifibrotic treatment due to side effects (14 with pirfenidone, 7 with nintedanib); no fatal adverse events were recorded. Discussion. Our results showed a similar effectiveness between pirfenidone and nintedanib in terms of mortality and functional disease progression. Both drugs confirmed their good tolerability profile and no new safety alerts were observed. Nintedanib was associated with a smaller reduction of DLCO after one year of follow-up compared with pirfenidone, maybe due to its antiangiogenic properties.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmolb.2020.581828

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 89

Metadata

Authors
Cameli, P., Refini, R. M., Bergantini, L., d’Alessandro, M., Alonzi, V., Magnoni, C., Rottoli, P., Sestini, P., & Bargagli, E.
Venue
Frontiers in Molecular Biosciences
Published
2020-09-04
Volume
7
Pages
581828-581828
ISSN
2296-889X (ISSN-L)
OpenAlex
W3083040024
Cited by
89
References
9
FWCI
6.53
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study. https://app.cochat.ai/papers/10.3389/fmolb.2020.581828
The paper
Cameli, P., Refini, R. M., Bergantini, L., d’Alessandro, M., Alonzi, V., Magnoni, C., Rottoli, P., Sestini, P., & Bargagli, E. (2020). Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study. Frontiers in Molecular Biosciences. https://doi.org/10.3389/fmolb.2020.581828

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.